Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VUM03
- Development stage
- Preclinical
- Lead developer
- Vcanbiopharma
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Injection
01
Overview
VUM03 is an allogeneic mesenchymal stem cell (MSC) therapy developed by Eastern Union Stem Cell & Gene Engineering (Vcanbio). It is specifically developed for the treatment of complex perianal fistulas in patients with inactive or mildly active Crohn's disease. The therapy leverages the innate ability of mesenchymal stem cells to modulate the immune response and promote tissue regeneration, aiming to facilitate the healing and closure of complex fistulous tracts. VUM03 is formulated as an injection and has received Investigational New Drug (IND) approval from the National Medical Products Administration (NMPA) in China.
- Other names
- VUM03 注射液
Beyond the preview
Go deeper on VUM03.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VUM03.